Acrylamide-induced carcinogenicity in mouse lung involves mutagenicity: CII gene mutations in the lung of big blue mice exposed to acrylamide and glycidamide for up to 4 weeks

Environmental and Molecular Mutagenesis

Volumn 56, Issue 5, 2015, Pages 446-456

  Manjanatha, Mugimane G ^a   Guo, Li Wu ^a   Shelton, Sharon D ^a   Doerge, Daniel R ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Acrylamide; Carcinogenicity; cII mutant frequency; DNA adducts; Glycidamide

Indexed keywords

ACRYLAMIDE; DRINKING WATER; GENOMIC DNA; GLYCIDAMIDE; CII PROTEIN, BACTERIOPHAGE LAMBDA; DNA; EPOXIDE; MUTAGENIC AGENT; TRANSCRIPTION FACTOR; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DRUG CARCINOGENICITY; FEMALE; FRAMESHIFT MUTATION; GENETIC ANALYSIS; GENOTOXICITY; LUNG CARCINOGENESIS; MALE; MOUSE; MUTAGENICITY; MUTATION RATE; NONHUMAN; SEQUENCE ANALYSIS; ANIMAL; CHEMICALLY INDUCED; DNA SEQUENCE; DOSE RESPONSE; GENETICS; INBRED MOUSE STRAIN; LUNG TUMOR; METABOLISM; MUTATION; ORAL DRUG ADMINISTRATION; SEXUAL DEVELOPMENT;

MUS; RODENTIA;

ACRYLAMIDE; ADMINISTRATION, ORAL; ANIMALS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; FEMALE; LUNG NEOPLASMS; MALE; MICE, INBRED STRAINS; MUTAGENS; MUTATION; SEQUENCE ANALYSIS, DNA; SEX CHARACTERISTICS; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

EID: 84931047985     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21939     Document Type: Article

References (43)

1. Atay NZ, Calgan D, Ozakat E, Varnali T. 2005. Acrylamide and glycidamide adducts of guanine. J Mol Struct: Theochem 728:249-251.
2. Beland FA, Mellick PW, Olson GR, Mendoza MCB, Marques MM, Doerge DR. 2013. Carcinogenicity of acrylamide in B6C3F1 mice and F344/N rats from a 2-year drinking water exposure. Food Chem Toxicol 51:149-159.
3. Besaratinia A, Pfeifer GP. 2005. G.P. DNA adduction and mutagenic properties of Acrylamide. Mutat Res 580:31-40.
4. Besaratinia A, Pfeifer GP. 2007. A review of mechanisms of acrylamide carcinogenicity. Carcinogenesis 28:519-528.
5. Bergmark E, Calleman CJ, He F, Costa LG. 1993. Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol Appl Pharmacol 120:45-54.
6. Cabral Neto JB, Cabral RE, Margot A, Le Page F, Sarasin A, Gentil A. 1994. Coding properties of a unique apurinic/apyrimidinic site replicated in mammalian cells. J Mol Biol 240:416-420.
7. Calleman CJ, Bergmark E, Costa LG. 1990. Acrylamide is metabolized to glycidamide in the rat: Evidence from hemoglobin adduct formation. Chem Res Toxicol 3:406-412.
8. Cariello NF, Piegorsch WW, Adams WT, Skopek TR. 1994. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 15:2281-2285.
9. Doerge DR, Young JF, McDaniel P, Twaddle NC, Churchwell MI. 2005a. Toxicokinetics of acrylamide and glycidamide in B6C3F1 mice. Toxicol Appl Pharmacol 202:258-267.
10. Doerge DR, Gamboa da Costa GG, McDaniel LP, Churchwell MI, Twaddle NC, Beland FA. 2005b. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. Mutat Res 580:131-141.
11. Fennell TR, Friedman MA. 2006. Comparison of acrylamide metabolism in humans and rodents. Adv Exp Med Biol 561:109-116.
12. Fennell TR, Snyder RW, Krol WL, Sumner SC. 2003. Comparison of the hemoglobin adducts formed by administration of N-methylolacrylamide and acrylamide to rats. Toxicol Sci 71:164-175.
13. Fennell TR, Sumner SC, Snyder RW, Burgess J, Spicer R, Bridson WE, Friedman MA. 2005. Metabolism and hemoglobin adduct formation of acrylamide in humans. Toxicol Sci 85:447-459.
14. Gamboa da Costa G, Churchwell MI, Hamilton LP, Von Tungeln LS, Beland FA, Marques MM, Doerge DR. 2003. DNA adduct formation from acrylamide via conversion to glycidamide in adult and neonatal mice. Chem Res Toxicol 16:1328-1337.
15. Ghanayem BI, Witt KL, El-Hadri L, Hoffler U, Kissling GE, Shelby MD, Bishop JB. 2005. Comparison of germ cell mutagenicity in male CYP2E1-null and wild-type mice treated with acrylamide: Evidence supporting a glycidamide-mediated effect. Biol Reprod 72:157-163.
16. Gentil A, Renault G, Madzak C, Margot A, Cabral-Neto JB, Vasseur JJ, Rayner B, Imbach JL, Sarasin A. 1990. Mutagenic properties of a unique abasic site in mammalian cells. Biochem Biophys Res Commun 173:704-710.
17. Glaab WE, Tindall KR, Skopek TR. 1999. Specificity of mutations induced by methyl methanesulfonate in mismatch repair-deficient human cancer cell lines. Mutat Res 427:67-78.
18. Hagmar L, Tornqvist M, Nordander C, Rosen I, Bruze M, Kautiainen A, Magnusson AL, Malmberg B, Aprea P, Granath F, Axmon A. 2001. Health effects of occupational exposure to acrylamide using hemoglobin adducts as biomarkers of internal dose. Scand J Work Environ Health 27:219-226.
19. Harbach PR, Zimmer DM, Filipunas AL, Mattes WB, Aaron CS. 1999. Spontaneous mutation spectrum at the cII locus in liver, lung, and spleen tissue of BB transgenic mice. Environ Mol Mutagen 33:132-143.
20. Hernandez LG, Forkert PG. 2007. In vivo mutagenicity of vinyl carbamate and ethyl carbamate in lung and small intestine of F1 (big Blue X A/J) transgenic mice. Int J Cancer 120:1426-1433.
21. International Agency for Research on Cancer. 1995. Acrylamide. IARC Monograph Series, Vol. 60. pp 1-45.
22. Klinedinst DK, Drinkwater NR. 1992. Mutagenesis by apurinic sites in normal and ataxia telangiectasia human lymphoblastoid cells. Mol Carcinogen 6:32-42.
23. Koskinen M, Plna K. 2000. Specific DNA adducts induced by some mono-substituted epoxides in vitro and in vivo. Chem Biol Interact 129:209-229.
24. Loeb LA, Preston BD. 1986. Mutagen by apurinic/apyrimidinic sites. Annu Rev Genet 20:201-230.
25. Male R, Haukanes BI, Helland DE, Kleppe K. 1987. Substrate specificity of 3-methyladenine-DNA glycosylase from calf thymus. Eur J Biochem 165:13-19.
26. Manjanatha MG, Aidoo A, Shelton SD, Bishop ME, McDaniel LP, Lyn-Cook LE, Doerge DR. 2006. Genotoxicity of acrylamide and its metabolite glycidamide administered in drinking water to male and female big blue mice. Environ Mol Mutagen 47:6-17.
27. Mucci LA, Wilson KM. 2008. Acrylamide intake through diet and human risk. J Agric Food Chem 56:6013-6019.
28. National Toxicology Program. 2012. Toxicology and carcinogenesis studies of acrylamide (CAS No. 79-06-1) in F344/N rats and B6C3F1 mice (feed and drinking water studies). NTP TR 575, NIH Publication No. 12-5917. Research Triangle Park, NC.
29. Paulsson B, Grawe J, Tornqvist M. 2002. Hemoglobin adducts and micronucleus frequencies in mouse and rat after acrylamide or N-methylolacrylamide treatment. Mutat Res 516:101-111.
30. Petersen BJ, Tran N. 2005. Exposure to acrylamide: placing exposure in context. Adv Exp Med Biol 561:63-76.
31. Randall SK, Eritja R, Kaplan BE, Petruska J, Goodman MF. 1987. Nucleotide insertion kinetics opposite abasic lesions in DNA. J Biol Chem 262:6864-6870.
32. Rosen J, Hellenas KE. 2002. Analysis of acrylamide in cooked foods by liquid chromatography tandem mass spectrometry. Analyst 127:880-882.
33. 14C]acrylamide. Carcinogenesis 16:1161-1165.
34. Solomon JJ, Fedyk J, Mukai F, Segal A. 1985. Direct alkylation of 2'-deoxynucleosides and DNA following in vitro reaction with acrylamide. Cancer Res 45:3465-3470.
35. 13C nuclear magnetic resonance spectroscopy. Chem Res Toxicol 5:81-89.
36. Sumner S, Fennell T, Moore T, Chanas B, Gonzalez F, Ghanayem B. 1999. Role or cytochrome p450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 12:1110-1116.
37. Tareke E, Rydberg P, Karlsson P, Eriksson S, Tornqvist M. 2002. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric Food Chem 50:4998-5006.
38. Tareke E, Nathan C, Twaddle L, McDaniel P, Churchwell MI, Young JF, Doerge DR. 2006. Relationships between biomarkers of exposure and toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and glycidamide and multiple doses of acrylamide. Toxicol Appl Pharmacol 217:63-75.
39. Twaddle NC, McDaniel LP, Gamboa da Costa G, Churchwell MI, Beland FA, Doerge DR. 2004. Determination of acrylamide and glycidamide serum toxicokinetics in B6C3F1 mice using LC-ES/MS/MS. Cancer Letter 207:9-17.
40. Von Tungeln LS, Churchwell MI, Doerge DR, Shaddock JG, McGarrity LJ, Heflich RH, Gamboa da Costa G, Marques MM, Beland FA. 2009. DNA adduct formation and induction of micronuclei and mutation in B6C3F1/TK mice treated neonatally with acrylamide or glycidamide. Int J Cancer 124:2006-2015.
41. Von Tungeln LS, Doerge DR, Gamboa da Costa G, Marques MM, Witt WM, Koturbash I, Pogribny IP, Beland FA. 2012. Tumorigenicity of acrylamide and its metabolite glycidamide in the neonatal mouse bioassay. Int J Cancer 131:2008-2015.
42. Walker VE, Skopek TR. 1993. A mouse model for the study of in vivo mutational spectra: Sequence specificity of ethylene oxide at the hprt locus. Mutat Res 288:151-162.
43. Wang RS, McDaniel LP, Manjanatha MG, Shelton SD, Doerge DR, Mei N. 2010. Mutagenicity of acrylamide and glycidamide in the testes of Big Blue mice Toxicol Sci 117:72-80.